Kitada Munehiro, Ogura Yoshio, Koya Daisuke
Division of Anticipatory Molecular Food Science and Technology, Medical Research Institute; Department of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Department of Diabetology and Endocrinology, Kanazawa Medical University, Uchinada, Ishikawa, Japan.
Int J Nephrol Renovasc Dis. 2016 Nov 14;9:279-290. doi: 10.2147/IJNRD.S103784. eCollection 2016.
Diabetic nephropathy is the most common cause of end-stage renal disease. Therefore, novel therapies for the suppression of diabetic nephropathy must be developed. Rodent models are useful for elucidating the pathogenesis of diseases and testing novel therapies, and many type 1 and type 2 diabetic rodent models have been established for the study of diabetes and diabetic complications. Streptozotocin (STZ)-induced diabetic animals are widely used as a model of type 1 diabetes. Akita diabetic mice that have an +/ mutation and OVE26 mice that overexpress calmodulin in pancreatic β-cells serve as a genetic model of type 1 diabetes. In addition, mice, KK- mice, Zucker diabetic fatty rats, Wistar fatty rats, Otsuka Long-Evans Tokushima Fatty rats and Goto-Kakizaki rats serve as rodent models of type 2 diabetes. An animal model of diabetic nephropathy should exhibit progressive albuminuria and a decrease in renal function, as well as the characteristic histological changes in the glomeruli and the tubulointerstitial lesions that are observed in cases of human diabetic nephropathy. A rodent model that strongly exhibits all these features of human diabetic nephropathy has not yet been developed. However, the currently available rodent models of diabetes can be useful in the study of diabetic nephropathy by increasing our understanding of the features of each diabetic rodent model. Furthermore, the genetic background and strain of each mouse model result in differences in susceptibility to diabetic nephropathy with albuminuria and the development of glomerular and tubulointerstitial lesions. Therefore, the validation of an animal model reproducing human diabetic nephropathy will significantly facilitate our understanding of the underlying genetic mechanisms that contribute to the development of diabetic nephropathy. In this review, we focus on rodent models of diabetes and discuss the utility and limitations of these models for the study of diabetic nephropathy.
糖尿病肾病是终末期肾病最常见的病因。因此,必须研发出抑制糖尿病肾病的新疗法。啮齿动物模型有助于阐明疾病的发病机制并测试新疗法,目前已建立了许多1型和2型糖尿病啮齿动物模型用于糖尿病及其并发症的研究。链脲佐菌素(STZ)诱导的糖尿病动物被广泛用作1型糖尿病模型。携带+/突变的阿基塔糖尿病小鼠以及在胰腺β细胞中过表达钙调蛋白的OVE26小鼠用作1型糖尿病的遗传模型。此外,小鼠、KK-小鼠、 Zucker糖尿病肥胖大鼠、Wistar肥胖大鼠、大冢长-伊文斯德岛肥胖大鼠和Goto-Kakizaki大鼠用作2型糖尿病的啮齿动物模型。糖尿病肾病的动物模型应表现出进行性蛋白尿和肾功能下降,以及在人类糖尿病肾病病例中观察到的肾小球和肾小管间质病变的特征性组织学变化。目前尚未开发出能强烈表现出人类糖尿病肾病所有这些特征的啮齿动物模型。然而,通过加深我们对每种糖尿病啮齿动物模型特征的了解,目前可用的糖尿病啮齿动物模型可用于糖尿病肾病的研究。此外,每个小鼠模型的遗传背景和品系导致对糖尿病肾病伴蛋白尿以及肾小球和肾小管间质病变发展的易感性存在差异。因此,验证重现人类糖尿病肾病的动物模型将极大地促进我们对导致糖尿病肾病发展的潜在遗传机制的理解。在本综述中,我们重点关注糖尿病的啮齿动物模型,并讨论这些模型在糖尿病肾病研究中的实用性和局限性。